Edgar Filing: ORTHOFIX INTERNATIONAL N V

form10q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-Q

(Mark one)

x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2008

o	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from____________ to ____________

Commission File Number: 0-19961

ORTHOFIX INTERNATIONAL N.V.

(Exact name of registrant as specified in its charter)

	Netherlands Antilles		N/A
	(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

	7 Abraham de Veerstraat Curaçao Netherlands Antilles		N/A
	(Address of principal executive offices)		(Zip Code)

		599-9-4658525
	(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of “accelerated filer and large accelerated filer” in Rule 12b-2 of the Exchange Act. (Check one): Large Accelerated filer x Accelerated filer o Non-Accelerated filer o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x

As of November 7, 2008, 17,101,718 shares of common stock were issued and outstanding.

Table of Contents

PART I FINANCIAL INFORMATION
Item 1.	Condensed Consolidated Financial Statements	3
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	23
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	37
Item 4.	Controls and Procedures	38
PART II OTHER INFORMATION
Item 1.	Legal Proceedings	39
Item 1A.	Risk Factors	41
Item 6.	Exhibits	43
SIGNATURES		47

Forward-Looking Statements

This Form 10-Q contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, which relate to our business and financial outlook and which are based on our current beliefs, assumptions, expectations, estimates, forecasts and projections. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “projects,” “intends,” “predicts,” “potential” or “continue” or other comparable terminology. These forward-looking statements are not guarantees of our future performance and involve risks, uncertainties, estimates and assumptions that are difficult to predict. Therefore, our actual outcomes and results may differ materially from those expressed in these forward-looking statements. You should not place undue reliance on any of these forward-looking statements. Further, any forward-looking statement speaks only as of the date on which it is made, and we undertake no obligation to update any such statement to reflect new information, the occurrence of future events or circumstances or otherwise.

Factors that could cause actual results to differ materially from those indicated by the forward-looking statements or that could contribute to such differences include, but are not limited to, risks relating to the expected sales of products, including recently launched products, unanticipated expenditures, changing relationships with customers, suppliers, strategic partners and lenders, unfavorable results in litigation matters, risks relating to the protection of intellectual property, changes to the reimbursement policies of third parties, changes to and interpretation of governmental regulation of medical devices, the impact of competitive products, changes to the competitive environment, the acceptance of new products in the market, conditions of the orthopedic industry and the economy, currency or interest rate fluctuations, corporate development and marketing development activities, including acquisitions and divestitures, unexpected costs or operating unit performance related to recent acquisitions, unexpected difficulties meeting covenants under our senior secured bank credit facility and the other risks described under Item 1A – “Business – Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2007 and Part II, Item 1A – “Risk Factors” in this Form 10-Q.

Table of Contents

PART I

FINANCIAL INFORMATION

Item 1.

Condensed Consolidated Financial Statements

CONDENSED CONSOLIDATED BALANCE SHEETS

(U.S. Dollars, in thousands except share data)	September 30,		December 31,
	2008		2007
Assets	(Unaudited)		(Note 2)
Current assets:
Cash and cash equivalents	$	10,286	$	25,064
Restricted cash		16,761		16,453
Trade accounts receivable, net		115,679		108,900
Inventories, net		97,368		93,952
Deferred income taxes		11,373		11,373
Prepaid expenses and other current assets		30,059		25,035
Total current assets		281,526		280,777
Investments, at cost		2,095		4,427
Property, plant and equipment, net		33,154		33,444
Patents and other intangible assets, net		55,354		230,305
Goodwill		187,353		319,938
Deferred taxes and other long-term assets		19,305		16,773
Total assets	$	578,787	$	885,664
Liabilities and shareholders’ equity
Current liabilities:
Bank borrowings	$	6,197	$	8,704
Current portion of long-term debt		3,337		3,343
Trade accounts payable		26,561		24,715
Other current liabilities		33,361		36,544
Total current liabilities		69,456		73,306
Long-term debt		288,370		294,588
Deferred income taxes		5,475		75,908
Other long-term liabilities		5,630		7,922
Total liabilities		368,931		451,724

Contingencies (Note 18)
Shareholders’ equity:
Common shares (17,101,718 and 17,038,304 shares issued at September 30, 2008 and December 31, 2007, respectively)		1,710		1,704
Additional paid-in capital		166,954		157,349
Retained earnings		30,364		258,201
Accumulated other comprehensive income		10,828		16,686
Total shareholders’ equity		209,856		433,940

Total liabilities and shareholders’ equity	$	578,787	$	885,664

The accompanying notes form an integral part of these condensed consolidated financial statements.

Table of Contents

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2008 AND 2007

(Unaudited, U.S. Dollars, in thousands except share and per share data)	Three Months Ended						Nine Months Ended
	2008			2007			2008			2007

Net sales	$	129,301		$	121,120		$	387,372		$	361,488
Cost of sales		47,998			30,742			117,284			94,546
Gross profit		81,303			90,378			270,088			266,942
Operating expenses
Sales and marketing		50,210			47,055			153,652			138,949
General and administrative		19,293			16,908			60,252			49,619
Research and development		6,447			5,953			19,400			18,313
Amortization of intangible assets		5,347			4,671			15,220			13,710
Impairment of goodwill and certain intangible assets		289,523			-			289,523			-
Gain on sale of Pain Care® operations		-			-			(1,570	)		-
		370,820			74,587			536,477			220,591
Operating income (loss)		(289,517	)		15,791			(266,389	)		46,351

Other income (expense), net
Interest expense, net		(4,249	)		(5,666	)		(13,708	)		(17,200	)
Loss on refinancing of senior secured term loan		(5,735	)		-			(5,735	)		-
Other, net		(3,822	)		519			(2,737	)		234
		(13,806	)		(5,147	)		(22,180	)		(16,966	)
Income (loss) before income taxes		(303,323	)		10,644			(288,569	)		29,385
Income tax (expense) benefit		66,072			(2,616	)		60,732			(7,902	)

Net (loss) income	$	(237,251	)	$	8,028		$	(227,837	)	$	21,483

Net income (loss) per common share - basic	$	(13.87	)	$	0.48		$	(13.33	)	$	1.30

Net income (loss) per common share - diluted	$	(13.87	)	$	0.48		$	(13.33	)	$	1.27

Weighted average number of common shares -basic		17,101,718			16,639,019			17,093,133			16,546,385

Weighted average number of common shares - diluted		17,101,718			16,889,303			17,093,133			16,925,084

The accompanying notes form an integral part of these condensed consolidated financial statements.

Table of Contents

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2008 AND 2007

(Unaudited, U.S. Dollars, in thousands)	2008			2007

Cash flows from operating activities:
Net income (loss)	$	(227,837	)	$	21,483
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization		22,707			21,334
Amortization of debt costs		868			523
Provision for doubtful accounts		4,585			3,532
Deferred taxes		(76,861	)		(3,919	)
Share-based compensation		7,855			8,006
Change in inventory obsolescence estimate		10,913			-
Loss on refinancing of senior secured term loan		3,660			-
Impairment of goodwill and certain intangible assets		289,523			-
Impairment of investments held at cost		1,500			-
Amortization of step up of fair value in inventory		365			2,718
Gain on sale of Pain Care® operations		(1,570	)		-
Other		3,062			(1,328	)
Change in operating assets and liabilities:
Restricted cash		(352	)		(4,270	)
Accounts receivable		(13,805	)		(14,829	)
Inventories		(16,703	)		(19,086	)
Prepaid expenses and other current assets		(5,250	)		(5,976	)
Accounts payable		2,500			(2,707	)
Other current liabilities		(2,739	)		8,277
Net cash provided by operating activities		2,421			13,758

Cash flows from investing activities:
Payments made in connection with acquisitions and investments in subsidiaries, net of cash acquired		(501	)		(2,117	)
Capital expenditures		(15,831	)		(23,752	)
Proceeds from sale of investment held at cost		766			-
Proceeds from sale of Pain Care® operations		5,980			-
Net cash used in investing activities		(9,586	)		(25,869	)

Cash flows from financing activities:
Net proceeds from issuance of common shares		1,734			6,799
Repayments of long-term debt, net		(6,223	)		(6,505	)
Proceeds from (repayments of) bank borrowings, net		(2,377	)		7,870
Payment of refinancing fees		(283	)		-
Tax benefit on non-qualified stock options		22			1,164
Net cash (used in) provided by financing activities		(7,127	)		9,328
Effect of exchange rate changes on cash		(486	)		464
Net decrease in cash and cash equivalents		(14,778	)		(2,319	)
Cash and cash equivalents at the beginning of the year		25,064			25,881
Cash and cash equivalents at the end of the period	$	10,286		$	23,562

The accompanying notes form an integral part of these condensed consolidated financial statements.

Table of Contents

NOTES TO THE CONDENSED UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1:

BUSINESS

Orthofix International N.V. (the “Company”) is a multinational corporation principally involved in the design, development, manufacture, marketing and distribution of medical devices, principally for the orthopedic products market.

NOTE 2:

BASIS OF PRESENTATION

The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Pursuant to these rules and regulations, certain information and note disclosures, normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States, have been condensed or omitted. In the opinion of management, all adjustments (consisting of normal recurring items) considered necessary for a fair presentation have been included. Operating results for the three and nine months ended September 30, 2008 are not necessarily indicative of the results that may be expected for the year ending December 31, 2008. The balance sheet at December 31, 2007 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. For further information, refer to the Consolidated Financial Statements and Notes thereto of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2007.

NOTE 3:

RECENTLY ISSUED ACCOUNTING STANDARDS

In December 2007, the FASB ratified Emerging Issues Task Force (EITF) Issue No. 07-1, “Accounting for Collaborative Arrangements” (EITF 07-1). EITF 07-1 provides guidance related to the classification of the payments between participants, the appropriate income statement presentation, as well as disclosures related to certain collaborative arrangements. EITF 07-1 is effective for fiscal years beginning after December 15, 2008 and will be adopted by the Company in the first quarter of 2009. Unless other authoritative guidance prevails, the Company will apply the guidance included in EITF 07-1 to collaborative arrangements entered into in 2008.

In May 2008, the Financial Accounting Standards Board (“FASB”) issued Statement of Financial Accounting Standards (“SFAS”) No. 162, “The Hierarchy of Generally Accepted Accounting Principles.” The Statement identified the sources of accounting principles and the framework for selecting the principles to be used in the preparation of financial statements that are presented in conformity with generally accepted accounting principles in the United States. The Statement is effective 60 days following the SEC’s approval of the Public Company Accounting Oversight Board amendments to AU Section 411, “The Meaning of Present Fairly in Conformity With Generally Accepted Accounting Principles.” We do not anticipate the adoption of SFAS No. 162 to have a material impact on the Company’s results of operations or financial position.

In September 2006, the FASB issued SFAS No. 157, “Fair Value Measurements.” The Statement defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles and expands disclosure related to the use of fair value measures in financial statements. The provisions of SFAS No. 157 were to be effective for fiscal years beginning after November 15, 2007. On February 6, 2008, the FASB agreed to defer the effective date of SFAS No. 157 for one year for certain nonfinancial assets and nonfinancial liabilities, except those that are recognized or disclosed at fair value in the financial statements on a recurring basis (at least annually). Effective January 1, 2008, the Company adopted SFAS No. 157 except as it applies to those nonfinancial assets and nonfinancial liabilities. The adoption of SFAS No. 157 did not have a material impact on the Company’s results of operations or financial position.

Effective January 1, 2008, the Company adopted SFAS No. 159, “The Fair Value Option for Financial Assets and Financial Liabilities – including an amendment of FASB Statement No. 115.” SFAS No. 159 allows an entity the irrevocable option to elect fair value for the initial and subsequent measurement of certain financial assets and liabilities under an instrument-by-instrument election. Subsequent measurements for the financial assets and liabilities an entity elects to fair value will be recognized in the results of operations. SFAS No. 159 also establishes additional disclosure requirements. The Company did not elect the fair value option under SFAS No. 159 for any of its financial assets or liabilities upon adoption. The adoption of SFAS No. 159 did not have a material impact on the Company’s results of operations or financial position.

Table of Contents

In March 2008, the FASB issued SFAS No. 161, “Disclosures about Derivative Instruments and Hedging Activities, an amendment of FASB Statement No. 133.” SFAS No. 161 requires entities to provide greater transparency through additional disclosures about (a) how and why an entity uses derivative instruments, (b) how derivative instruments and related hedged items are accounted for under SFAS No. 133 “Accounting for Derivative Instruments and Hedging Activities” and its related interpretations, and (c) how derivative instruments and related hedged items affect an entity’s financial position, results of operations, and cash flows. SFAS No. 161 is effective for financial statements issued for fiscal years and interim periods beginning after November 15, 2008. The Company is currently evaluating the potential impact of adopting SFAS No. 161 on the Company’s disclosures of its derivative instruments and hedging activities.

In December 2007, the FASB issued SFAS No. 141(R), “Business Combinations (revised 2007).” SFAS No. 141(R) amends SFAS No. 141, “Business Combinations,” and provides revised guidance for recognizing and measuring identifiable assets and goodwill acquired, liabilities assumed, and any noncontrolling interest in the acquiree. It also provides disclosure requirements to enable users of the financial statements to evaluate the nature and financial effects of the business combination. SFAS No. 141(R) is effective for fiscal years beginning after December 15, 2008 and is to be applied prospectively. The Company is currently evaluating the potential impact of adopting SFAS No. 141(R) on its consolidated financial position and results of operations.

In December 2007, the FASB issued SFAS No. 160, “Noncontrolling Interests in Consolidated Financial Statements, an Amendment of ARB 51,” which establishes accounting and reporting standards pertaining to ownership interest in subsidiaries held by parties other than the parent, the amount of net income attributable to the parent and to the noncontrolling interest, changes in a parent’s ownership interest, and the valuation of any retained noncontrolling equity investment when a subsidiary is deconsolidated. SFAS No. 160 also establishes disclosure requirements that clearly identify and distinguish between the interests of the parent and the interests of the noncontrolling owners. SFAS No. 160 is effective for fiscal years beginning on or after December 15, 2008. The Company is currently evaluating the potential impact of adopting SFAS No. 160 on its consolidated financial position and results of operations.

NOTE 4:

SHARE-BASED COMPENSATION

The Company accounts for its share-based compensation plans in accordance with SFAS No. 123(R), “Share-Based Payment”, using the modified prospective transition method. Under SFAS No. 123(R), all share-based compensation costs are measured at the grant date, based on the estimated fair value of the award, and are recognized as expense in the statement of operations over the requisite service period. Commencing in June 2007, the Company offered restricted shares in addition to stock options as a form of share-based compensation.

Table of Contents

The following table shows the detail of share-based compensation by line item in the Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2008 and 2007:

(In US$ thousands)	Three Months Ended September 30,				Nine Months Ended September 30,
	2008		2007		2008		2007

Cost of sales	$	-	$	113	$	116	$	293

Sales and marketing (1)		579		800		1,353		1,993

General and administrative		2,433		1,846		5,793		4,978

Research and development		186		126		593		742

Total	$	3,198	$	2,885	$	7,855	$	8,006

(1) There are no performance requirements and there was no consideration received for share-based compensation awarded to sales and marketing employees.

NOTE 5:

RECLASSIFICATIONS

Certain prior year amounts have been reclassified to conform to the 2008 presentation. The reclassifications have no effect on previously reported net income or shareholders’ equity.

NOTE 6:

INVENTORIES

Inventories are valued at the lower of cost or estimated net realizable value, after provision for excess or obsolete items. Cost is determined on a weighted-average basis, which approximates the FIFO method. The valuation of work-in-process, finished goods, field inventory and consignment inventory includes the cost of materials, labor and production. Field inventory represents immediately saleable finished goods inventory that is in the possession of the Company’s direct sales representatives.

Inventories were as follows:

	September 30,			December 31,
(In US$ thousands)	2008			2007

Raw materials	$	9,302		$	10,804
Work-in-process		6,998			6,100
Finished goods		57,840			42,384
Field inventory (as described above)		12,368			13,997
Consignment inventory		33,563			30,560
		120,071			103,845
Less reserve for obsolescence		(22,703	)		(9,893	)
	$	97,368		$	93,952

In the quarter ended September 30, 2008, due to reduced projections in revenue, distributor terminations, new products, and the replacement of one product with a successor product, the Company changed its estimates regarding the inventory allowance at Blackstone, primarily based on estimated net realizable value using assumptions about future demand and market conditions. The change in estimate resulted in an increase in the reserve for obsolescence of approximately $10.9 million ($7.0 million net of tax or $0.41 per basic and diluted share).

Table of Contents

NOTE 7:

GOODWILL

The changes in the net carrying value of goodwill by reportable segment for the period ended September 30, 2008 are as follows:

(In US$ thousands)	Domestic		Blackstone			Breg			International			Total
At December 31, 2007	$	31,793	$	136,240		$	101,322		$	50,583		$	319,938

Disposals (1)		-		-			(2,027	)		-			(2,027	)

Purchase price adjustment (2)		-		-			-			(248	)		(248	)

Impairment (3)		-		(126,873	)		-			-			(126,873	)

Foreign currency		-		-			-			(3,437	)		(3,437	)

At September 30, 2008	$	31,793	$	9,367		$	99,295		$	46,898		$	187,353

(1)

Sale of operations relating to the Pain Care® business at Breg during the first quarter of 2008.

(2)

Principally relates to the acquisition of the remaining 38.74% of the minority interest in the Company’s Mexican subsidiary and the remaining 10.5% of the minority interest in the Company’s Brazilian subsidiary during the first and third quarters of 2008, respectively.

(3)

In accordance with SFAS No. 142, “Goodwill and Other Intangible Assets,” the Company performed an impairment analysis of indefinite-lived intangibles. As part of the Company's debt refinancing completed in September 2008, five year projections were prepared for Blackstone. Due to the recent trend of decreasing revenues at Blackstone, the Company evaluated the goodwill at Blackstone. The fair value of the Blackstone reporting unit was estimated using a combination of the income approach, which estimates the fair value of the reporting units based on the expected present value of future cash flows and the market approach, which estimates the fair value of the reporting units based on comparable market prices. The impairment analysis resulted in a goodwill impairment charge of $126.9 million because the carrying value exceeded the implied fair value of goodwill .

NOTE 8:

PATENTS AND OTHER INTANGIBLE ASSETS

(In US$ thousands)	September 30, 2008			December 31, 2007
Cost
Patents and other	$	33,233		$	107,235
Trademarks – definite lived (subject to amortization)		682			714
Trademarks – indefinite lived (not subject to amortization)		23,876			80,844
Distribution networks		44,586			98,586
		102,377			287,379
Accumulated amortization
Patents and other		(20,826	)		(28,254	)
Trademarks – definite lived (subject to amortization)		(657	)		(559	)
Distribution networks		(25,540	)		(28,261	)
	$	55,354		$	230,305

Table of Contents

Amortization expense for intangible assets is estimated to be approximately $2.4 million for the remainder of 2008 and $8.5 million, $7.8 million, $7.2 million, $6.8 million and $5.9 million for the periods ending December 31, 2009, 2010, 2011, 2012, and 2013 respectively.

During the third quarter of 2008, the Company determined that a test for impairment of goodwill in accordance with SFAS No. 142 “Goodwill and Other Intangible Assets,” was necessary due to Blackstone projections prepared in connection with the Company’s debt refinancing completed in September 2008, being materially different than projections used in Blackstone’s original purchase accounting. The Company evaluated the indefinite-lived intangible assets which included the Blackstone Trademark acquired during the acquisition of Blackstone. The impairment analysis resulted in the carrying value of the Trademark exceeding the fair value for which there is a $57.0 million impairment charge included in Impairment of Goodwill and Certain Intangible Assets.

Also, during the third quarter of 2008, the Company determined that a Triggering Event as defined by SFAS No. 144 “Accounting for the Impairment or Disposal of Long-Lived Assets” occurred with respect to the definite-lived intangibles at Blackstone. Due to the Triggering Event, the Company compared the expected cash flows to be generated by the definite-lived intangibles on an undiscounted basis to the carrying value of the intangible asset. The Company determined the carrying value exceeded the undiscounted cash flow and impaired the distribution network and technologies at Blackstone to their fair value which resulted in an impairment charge of $105.7 million which is included in Impairment of Goodwill and Certain Intangible Assets.

NOTE 9:

BANK BORROWINGS

(In US$ thousands)		September 30, 2008				December 31, 2007
Borrowings under line of credit		$	6,197			$	8,704

The weighted average interest rates on borrowings under lines of credit as of September 30, 2008 and December 31, 2007 were 6.97% and 4.79%, respectively.

Borrowings under lines of credit consist of borrowings in Euros. The Company had unused available lines of credit of 2.9 million Euros ($4.1 million) and 1.3 million Euros ($2.0 million) at September 30, 2008 and December 31, 2007, respectively, in its Italian line of credit, which gives the Company the option to borrow amounts in Italy at rates which are determined at the time of borrowing. This line of credit is unsecured.

NOTE 10:

LONG-TERM DEBT

(In US$ thousands)	September 30, 2008			December 31, 2007

Long-term obligations	$	291,525		$	297,700
Other loans		182			231
		291,707			297,931
Less current portion		(3,337	)		(3,343	)
	$	288,370		$	294,588

On September 22, 2006 the Company’s wholly-owned U.S. holding company subsidiary, Orthofix Holdings, Inc. (“Orthofix Holdings”), entered into a senior secured credit facility with a syndicate of financial institutions to finance the acquisition of Blackstone. Certain terms of the senior secured credit facility were amended September 29, 2008. The senior secured credit facility provides for (1) a seven-year amortizing term loan facility of $330.0 million, the proceeds of which, together with cash balances were used for payment of the purchase price of Blackstone; and (2) a six-year revolving credit facility of $45.0 million. As of September 30, 2008, the Company had no amounts outstanding under the revolving credit facility and $291.5 million outstanding under the term loan facility. Obligations under the senior secured credit facility have a floating interest rate of the London Inter-Bank Offered Rate (“LIBOR”) plus a margin or prime rate plus a margin. Currently, the term loan is a LIBOR loan, and the margin is 4.50%, which is adjusted quarterly based upon the leverage ratio of the Company and its subsidiaries. In June 2008, the Company entered into an interest rate swap agreement to manage its interest rate exposure on LIBOR borrowings; see Note 16, Derivative Instruments, for further detail. The effective interest rates as of September 30, 2008 and December 31, 2007 on the senior secured credit facility were 8.2% and 6.6%, respectively.

Table of Contents

Each of the domestic subsidiaries of the Company (which includes Orthofix Inc., Breg Inc., and Blackstone) and Colgate Medical Limited and Victory Medical Limited (wholly-owned financing subsidiaries of the Company) have guaranteed the obligations of Orthofix Holdings under the senior secured credit facility. The obligations of the subsidiaries under their guarantees are secured by the pledges of their respective assets.

In conjunction with obtaining the senior secured credit facility, the Company incurred debt issuance costs of $6.4 million which it has been amortizing over the life of the facility. A portion of the capitalized debt issuance costs included in other long-term assets related to the senior secured credit facility were expensed as a result of the amendment on September 29, 2008, and are included in the loss on refinancing of senior secured term loan. In connection with the amendment to the credit facility, the Company paid additional fees of $2.4 million in the quarter ended September 30, 2008, of which $2.1 million are included in the loss on refinancing of senior secured term loan.. As of September 30, 2008, $0.8 million of debt issuance costs which relate to the Company’s revolving credit facility are included in other long-term assets compared to debt issuance costs related to the senior secured term loan and the revolving credit facility which were $5.2 million at December 31, 2007.

Certain subsidiaries of the Company have restrictions on their ability to pay dividends or make intercompany loan advances pursuant to the Company’s senior secured credit facility. The net assets of Orthofix Holdings and its subsidiaries are restricted for distributions to the parent company. Domestic subsidiaries of the Company as parties to the credit agreement have access to these net assets for operational purposes. The amount of restricted net assets of Orthofix Holdings and its subsidiaries as of September 30, 2008 is $6.4 million compared to $300.7 million at December 31, 2007.

In addition, the Company’s senior secured credit facility contains certain financial covenants, including a fixed charge coverage ratio and a leverage ratio applicable to Orthofix and its subsidiaries on a consolidated basis. A breach of any of these covenants could result in an event of default under the credit agreement, which could permit acceleration of the debt payments under the facility unless such breach is waived by the lenders, who are a party to the agreement, or the agreement is amended. Management believes the Company was in compliance with these financial covenants as measured at September 30, 2008.

NOTE 11:

COMMON SHARES

For the nine months ended September 30, 2008, the Company issued 63,414 shares of common stock upon the exercise of outstanding stock options, vesting of restricted stock, and shares issued pursuant to its employee stock purchase plan for net proceeds of $1.7 million.

NOTE 12:

COMPREHENSIVE INCOME (LOSS)

Accumulated other comprehensive income (loss) is comprised of foreign currency translation adjustments and the effective portion of the gain (loss) for derivatives designated and accounted for as cash flow hedges. The components of and changes in other comprehensive income (loss) are as follows:

Table of Contents

(In US$ thousands)	Foreign Currency Translation Adjustments			Fair Value of Derivatives			Accumulated Other Comprehensive Income/(Loss)
Balance at December 31, 2007	$	15,156		$	1,530		$	16,686
Unrealized loss on derivative instruments, net of tax of $(71)		-			(76	)		(76	)
Foreign currency translation adjustment		(5,782	)		-			(5,782	)
Balance at September 30, 2008	$	9,374		$	1,454		$	10,828

(In US$ thousands)	Three Months Ended September 30,						Nine Months Ended September 30,
	2008			2007			2008			2007
Net (loss) income	$	(237,251	)	$	8,028		$	(227,837	)	$	21,483

Other comprehensive income:
Unrealized loss on derivative instrument, net of tax		(1,997	)		(367	)		(76	)		(575	)
Foreign currency translation adjustment		(5,953	)		1,227			(5,782	)		2,699
Total comprehensive income (loss)	$	(245,201	)	$	8,888		$	(233,695	)	$	23,607

NOTE 13:

BUSINESS SEGMENT INFORMATION

The Company’s segment information is prepared on the same basis that the Company’s management reviews the financial information for operational decision making purposes. The Company is comprised of the following segments:

Domestic

Domestic (“Domestic”) consists of operations in the United States of Orthofix Inc., which designs, manufactures and distributes stimulation and orthopedic products. Domestic uses both direct and distributor sales representatives to sell Spine and Orthopedic products to hospitals, doctors and other healthcare providers in the United States market.

Blackstone

Blackstone (“Blackstone”) consists of Blackstone Medical, Inc., based in Springfield, Massachusetts and its two subsidiaries, Blackstone GmbH and Goldstone GmbH. Blackstone specializes in the design, development and marketing of spinal implant and related human cellular and tissue based products (“HCT/P products”, often referred to as Biologic products). Blackstone distributes its products through a network of domestic and international distributors, sales representatives and affiliates.

Breg

Breg (“Breg”) consists of Breg, Inc. Breg, based in Vista, California, designs, manufactures, and distributes orthopedic products for post-operative reconstruction and rehabilitative patient use and sells its products through a network of domestic and international distributors, sales representatives and affiliates.

International

International (“International”) consists of international operations located in Europe, Mexico, Brazil and Puerto Rico, as well as independent distributors located outside the United States. International uses both direct and distributor sales representatives to sell Spine, Orthopedics, Sports Medicine, Vascular and Other products to hospitals, doctors, and other healthcare providers.

Table of Contents

Group Activities

Group Activities are comprised of the Parent’s and Orthofix Holdings’ operating expenses and identifiable assets.

The following tables below present information by reportable segment for the three and nine month periods ended September 30:

For the three month period ended September 30:

	External Sales				Intersegment Sales
(In US$ thousands)	2008		2007		2008		2007
Domestic	$	47,065	$	41,971	$	1,552	$	858
Blackstone		25,338		29,448		349		1,012
Breg		22,377		21,206		1,392		1,337
International		34,521		28,495		6,240		5,958
Total	$	129,301	$	121,120	$	9,533	$	9,165

For the nine month period ended September 30:

	External Sales				Intersegment Sales
(In US$ thousands)	2008		2007		2008		2007
Domestic	$	138,397	$	122,718	$	4,856	$	3,137
Blackstone		81,093		85,859		2,938		2,449
Breg		66,341		61,522		4,048		2,561
International		101,541		91,389		19,673		22,108
Total	$	387,372	$	361,488	$	31,515	$	30,255

The following table presents operating income (loss) by segment for the three and nine month periods ended September 30:

Table of Contents

Operating Income (Loss)	Three Months Ended September 30,						Nine Months Ended September 30,
(In US$ thousands)	2008			2007			2008			2007

Domestic	$	17,155		$	14,050		$	47,235		$	42,124

Blackstone (1)		(309,201	)		(816	)		(319,993	)		(2,164	)

Breg		2,206			2,686			9,273			6,013

International		4,741			4,230			14,451			14,824

Group Activities		(4,309	)		(3,735	)		(16,525	)		(11,644	)

Eliminations		(109	)		(624	)		(830	)		(2,802	)

Total	$	(289,517	)	$	15,791		$	(266,389	)	$	46,351

(1) Includes impairment charges of $289.5 million during the three and nine months ended September 30, 2008 for goodwill and certain intangible assets

The following tables present sales by market sector for the three and nine month periods ended September 30, 2008 and 2007:

	Sales by Market Sector for the three month period ended September 30, 2008
(In US$ thousands)	Orthofix Domestic		Blackstone		Breg		Orthofix International		Total

Spine	$	35,340	$	25,338	$	-	$	640	$	61,318
Orthopedics		11,725		-		-		22,099		33,824
Sports Medicine		-		-		22,377		1,323		23,700
Vascular		-		-		-		4,274		4,274
Other		-		-		-		6,185		6,185

Total	$	47,065	$	25,338	$	22,377	$	34,521	$	129,301

Table of Contents

	Sales by Market Sector for the three month period ended September 30, 2007
(In US$ thousands)	Orthofix Domestic		Blackstone		Breg		Orthofix International		Total

Spine	$	31,693	$	29,448	$	-	$	168	$	61,309
Orthopedics		10,278				-		16,026		26,304
Sports Medicine		-		-		21,206		869		22,075
Vascular		-		-		-		4,718		4,718
Other		-		-		-		6,714		6,714

Total	$	41,971	$	29,448	$	21,206	$	28,495	$	121,120

	Sales by Market Sector for the nine month period ended September 30, 2008
(In US$ thousands)	Orthofix Domestic		Blackstone		Breg		Orthofix International		Total

Spine	$	104,143	$	81,093	$	-	$	1,252	$	186,488
Orthopedics		34,254		-		-		62,665		96,919
Sports Medicine		-		-		66,341		3,871		70,212
Vascular		-		-		-		13,391		13,391
Other		-		-		-		20,362		20,362

Total	$	138,397	$	81,093	$	66,341	$	101,541	$	387,372

Table of Contents

	Sales by Market Sector for the nine month period ended September 30, 2007
(In US$ thousands)	Orthofix Domestic		Blackstone		Breg		Orthofix International		Total

Spine	$	92,650	$	85,859	$	-	$	421	$	178,930
Orthopedics		30,068		-		-		51,865		81,933
Sports Medicine		-		-		61,522		3,033		64,555
Vascular		-		-		-		15,217		15,217
Other		-		-		-		20,853		20,853

Total	$	122,718	$	85,859	$	61,522	$	91,389	$	361,488

The following table presents identifiable assets by segment, excluding intercompany balances and investments in consolidated subsidiaries.

Identifiable Assets

(In US$ thousands)	September 30, 2008			December 31, 2007

Domestic	$	112,807		$	118,178

Blackstone (1)		122,828			404,788

Breg		174,911			180,157

International		173,839			177,586

Group activities		10,198			20,063

Eliminations		(15,796	)		(15,108	)

Total	$	578,787		$	885,664

(1) Includes impairment charges related to goodwill and certain intangibles of $289.5 million recorded as of September 30, 2008

NOTE 14:

INCOME TAXES

The difference between the reported benefit for income taxes and the tax benefit computed by applying the statutory rates applicable to each subsidiary of the Company is principally related to an impairment charge to goodwill for which the Company receives no tax benefit. Further, the effective tax rate has been positively affected by the Company’s European restructuring in 2006 and a similar transaction in 2002, whereby certain intangible assets were sold between subsidiaries in order to optimize the Company’s supply chain. Such assets were sold at estimates of fair value based upon valuations which remain subject to review by the local taxing authorities. Further, the effective tax rate has been affected by the generation of un-utilizable net operating losses in various jurisdictions, and the Section 199 deduction related to income attributable to production activities occurring in the United States.

Table of Contents

As of September 30, 2008, the Company’s gross unrecognized tax benefit was $1.7 million plus $0.5 million accrued for interest and penalties. The entire $1.7 million of unrecognized tax benefit would affect the Company’s effective tax rate if recognized. It is anticipated that the Company will release approximately $1.0 million in tax reserves within the next twelve months for uncertain tax positions due to the expiration of certain statutes of limitations.

The Company recognizes accrued interest and penalties related to unrecognized tax benefits within its global operations in income tax expense. To the extent interest and penalties are not assessed with respect to uncertain tax positions, amounts accrued will be reduced and reflected as a reduction of the overall income tax provision. As of September 30, 2008, the Company had approximately $0.5 million of accrued interest and penalties related to uncertain tax positions.

The Company is subject to tax examinations in all major taxing jurisdictions in which it operates. The Company files a consolidated income tax return in the U.S. federal jurisdiction and numerous consolidated and separate income tax returns in many state and foreign jurisdictions. The following table summarizes these open tax years by major jurisdiction:

	Open Tax Year
	Examination in		Examination not yet
Jurisdiction	Progress		Initiated

United States		2004-2006	2007

Various States		1996-2005		1996-2007

Brazil		N/A		2004-2007

Cyprus		N/A		2005-2007

France		N/A		2002-2007

Germany		2003-2005		2006-2007

Italy		N/A		2003-2007

Mexico		N/A		2000-2007

Netherlands		N/A		2004-2007

Puerto Rico		N/A		N/A

Seychelles		N/A		N/A

Switzerland		N/A		2004-2007

United Kingdom		N/A		2005-2007

Table of Contents

NOTE 15:

EARNINGS PER SHARE

For the three and nine months ended September 30, 2008 and 2007, there were no adjustments to net income for purposes of calculating basic and diluted net income (loss) per common share. The following table is a reconciliation of the weighted average shares used in the basic and diluted net income (loss) per common share computations.

	Three Months Ended September 30,				Nine Months Ended September 30,
	2008		2007		2008		2007

Weighted average common shares - basic		17,101,718		16,639,019		17,093,133		16,546,385

Effect of dilutive securities		-		250,284		-		378,699

Weighted average common shares – diluted		17,101,718		16,889,303		17,093,133		16,925,084

No adjustment has been made in the three and nine months ended September 30, 2008 for any common stock equivalents because their effects would be anti-dilutive. For the three and nine month periods ended September 30, 2008, potentially dilutive shares totaled 4,638 and 37,496, respectively.

For the three and nine month periods ended September 30, 2007, the Company did not include 172,218 and 145,218 options, respectively, in the diluted shares outstanding calculation because their inclusion would have been anti-dilutive or because their exercise price exceeded the average market price of the Company’s common stock during the period.

NOTE 16:

DERIVATIVE INSTRUMENTS

In June 2008, the Company entered into a three year fully amortizable interest rate swap agreement (the “Swap”) with a notional amount of $150.0 million and an expiration date of June 30, 2011. The amount outstanding under the Swap as of September 30, 2008 was $150.0 million. Under the Swap the Company will pay a fixed rate of 3.73% and receive interest at floating rates based on the three month LIBOR rate at each quarterly re-pricing date until the expiration of the Swap. As of September 30, 2008 the interest rate on the debt related to the Swap was 8.2% (3.73% plus a margin of 4.50%). Our overall effective interest rate, including the impact of the Swap, as of September 30, 2008 on the senior secured debt was 8.2%. The instrument is designated as a cash flow hedge. The Company recognized an unrealized loss on the change in fair value of this swap arrangement of $1.0 million and $0.3 million, net of tax, for the three and nine months ended September 30, 2008, respectively.

In 2006, the Company entered into a cross-currency swap agreement to manage its foreign currency exposure related to a portion of the Company’s intercompany receivable of a U.S. dollar functional currency subsidiary that is denominated in Euro. The derivative instrument, a ten-year fully amortizable agreement with a notional amount of $63.0 million is scheduled to expire on December 30, 2016. The instrument is designated as a cash flow hedge. The amount outstanding under the agreement as of September 30, 2008 is $59.8 million. Under the agreement, the Company pays Euro and receives U.S. dollars based on scheduled cash flows in the agreement. The Company recognized an unrealized loss on the change in fair value of this swap arrangement of $1.0 million, net of tax, within other comprehensive income in the three months ended September 30, 2008. The Company recognized an unrealized gain on the change in fair value of this swap arrangement of $0.2 million, net of tax, within other comprehensive income in the nine months ended September 30, 2008.

NOTE 17:

FAIR VALUE MEASUREMENTS

Table of Contents

As described in Note 3, “Recently Issued Accounting Standards,” the Company adopted SFAS No. 157 effective January 1, 2008. SFAS No. 157 defines fair value as the price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. SFAS No. 157 also describes three levels of inputs that may be used to measure fair value:

Level 1 – quoted prices in active markets for identical assets and liabilities

Level 2 – observable inputs other than quoted prices in active markets for identical assets and liabilities

Level 3 – unobservable inputs in which there is little or no market data available, which require the reporting entity to develop its own assumptions

The fair value of the Company’s financial assets and liabilities measured at fair value on a recurring basis were as follows:

	Balance September 30, 2008			Level 1		Level 2			Level 3
Cash Equivalents	$	26		$	26	$	-		$	-

Derivative Financial Instruments(1)

Cash Flow Hedges	$	(2,176	)	$	-	$	(2,176	)	$	-

(1) See Note 16, “Derivative Instruments”.

NOTE 18:

CONTINGENCIES

Litigation

Effective October 29, 2007, the Company’s subsidiary, Blackstone, entered into a settlement agreement with respect to a patent infringement lawsuit captioned Medtronic Sofamor Danek USA Inc., Warsaw Orthopedic, Inc., Medtronic Puerto Rico Operations Co., and Medtronic Sofamor Danek Deggendorf, GmbH v. Blackstone Medical, Inc., Civil Action No. 06-30165-MAP, filed on September 22, 2006 in the United States District Court for the District of Massachusetts. In that lawsuit, the plaintiffs had alleged that (i) they were the exclusive licensees of United States Patent Nos. 6,926,718 B1, 6,936,050 B2, 6,936,051 B2, 6,398,783 B1 and 7,066,961 B2 (the “Patents”), and (ii) Blackstone's making, selling, offering for sale, and using within the United States of its Blackstone Anterior Cervical Plate, 3º Anterior Cervical Plate, Hallmark Anterior Cervical Plate and Construx Mini PEEK VBR System products infringed the Patents, and that such infringement was willful. The Complaint requested both damages and an injunction against further alleged infringement of the Patents. Blackstone denied infringement and asserted that the Patents were invalid. On July 20, 2007, the Company submitted a claim for indemnification from the escrow fund established in connection with the agreement and plan of merger between the Company, New Era Medical Corp. and Blackstone, dated as of August 4, 2006 (the “Merger Agreement”), for any losses to the Company or Blackstone resulting from this matter. The Company was subsequently notified by legal counsel for the former shareholders that the representative of the former shareholders of Blackstone has objected to the indemnification claim and intends to contest it in accordance with the terms of the Merger Agreement The settlement agreement is not expected to have a material impact on the Company’s consolidated financial position, results of operations or cash flows.

On or about July 23, 2007, Blackstone received a subpoena issued by the Department of Health and Human Services, Office of Inspector General, under the authority of the federal healthcare anti-kickback and false claims statutes. The subpoena seeks documents for the period January 1, 2000 through July 31, 2006, which is prior to Blackstone’s acquisition by the Company. The Company believes that the subpoena concerns the compensation of certain physician consultants and related matters. On September 17, 2007, the Company submitted a claim for indemnification from the escrow fund established in connection with the Merger Agreement for any losses to the Company or Blackstone resulting from this matter. The Company was subsequently notified by legal counsel for the former shareholders that the representative of the former shareholders of Blackstone has objected to the indemnification claim and intends to contest it in accordance with the terms of the Merger Agreement.

Table of Contents

On or about January 7, 2008, the Company received a federal grand jury subpoena from the United States Attorney’s Office for the District of Massachusetts. The subpoena seeks documents for the period January 1, 2000 through July 15, 2007 from the Company, including its subsidiaries. The Company believes that the subpoena concerns the compensation of physician consultants and related matters, and further believes that it is associated with the Department of Health and Human Services, Office of Inspector General’s investigation of such matters. On September 18, 2008, the Company submitted a claim for indemnification from the escrow fund established in connection with the Merger Agreement for any losses to the Company or Blackstone resulting from this matter.

In connection with the matters described above involving the Department of Health and Human Services, Office of the Inspector General, and United States Attorney’s Office for the District of Massachusetts, the Company’s legal counsel has been informed by representatives of the Department of Justice (“DOJ”) that a qui tam lawsuit against Blackstone and another affiliate of the Company is pending in the U.S. District Court for the District of Massachusetts. The Company believes that the complaint alleges causes of action under the False Claims Act for alleged inappropriate payments and other items of value conferred on physician consultants. The Company further understands that the seal in this qui tam lawsuit has been partially lifted for the purpose of allowing DOJ to disclose to the Company the existence of the qui tam lawsuit and discuss the allegations in the complaint, but that the qui tam lawsuit otherwise remains under seal as required by law. The Company intends to defend vigorously against this lawsuit. On September 18, 2008, we submitted a claim for indemnification from the escrow fund established in connection with the Merger Agreement for any losses to the Company or Blackstone resulting from this matter.

On or about September 27, 2007, Blackstone received a federal grand jury subpoena issued by the United States’ Attorney’s Office for the District of Nevada (“USAO-Nevada”). The subpoena seeks documents for the period from January 1999 to the date of issuance of the subpoena. The Company believes that the subpoena concerns payments or gifts made by Blackstone to certain physicians. On September 18, 2008, the Company submitted a claim for indemnification from the escrow fund established in connection with the Merger Agreement for any losses to the Company or Blackstone resulting from this matter.

On February 29, 2008, Blackstone received a Civil Investigative Demand (“CID”) from the Massachusetts Attorney General’s Office, Public Protection and Advocacy Bureau, Healthcare Division. The Company believes that the CID seeks documents concerning Blackstone’s financial relationships with certain physicians and related matters for the period from March 2004 through the date of issuance of the CID. On September 18, 2008, the Company submitted a claim for indemnification from the escrow fund established in connection with the Merger Agreement for any losses to the Company or Blackstone resulting from this matter.

The Ohio Attorney General’s Office, Health Care Fraud Section has issued a criminal subpoena, dated August 8, 2008, to Orthofix, Inc (the “Ohio AG Subpoena”). The Ohio AG Subpoena seeks documents for the period from January 1, 2000 through the date of issuance of the subpoena. The Company believes that the Ohio AG Subpoena arises from a government investigation that concerns the compensation of physician consultants and related matters. On September 18, 2008, the Company submitted a claim for indemnification from the escrow fund established in connection with the Merger Agreement for any losses to the Company or Blackstone resulting from this matter.

Blackstone is cooperating with the government’s request in each of the subpoenas set forth above and is in the process of responding to the subpoenas. The Company is unable to predict what actions, if any, might be taken by the governmental authorities that have issued these subpoenas or what impact, if any, the outcome of these matters might have on the Company’s consolidated financial positions, results of operations or cash flows.

By order entered on January 4, 2007, the United States District Court for the Eastern District of Arkansas unsealed a qui tam complaint captioned Thomas v. Chan, et al., 4:06-cv-00465-JLH, filed against Dr. Patrick Chan, Blackstone and other defendants including another device manufacturer. A qui tam action is a civil lawsuit brought by an individual for an alleged violation of a federal statute, in which the U.S. Department of Justice has the right to intervene and take over the prosecution of the lawsuit at its option. The complaint alleges causes of action under the False Claims Act for alleged inappropriate payments and other items of value conferred on Dr. Chan. On December 29, 2006, the U.S. Department of Justice filed a notice of non-intervention in the case. Plaintiff subsequently amended the complaint to add the Company as a defendant. On January 3, 2008, Dr. Chan pled guilty to one count of knowingly soliciting and receiving kickbacks from a medical device distributor in a criminal matter in which neither the Company nor any of its business units or employees were defendants. In January 2008, Dr. Chan entered into a settlement agreement with the plaintiff and certain governmental entities in the civil qui tam action, and on February 21, 2008, a joint stipulation of dismissal of claims against Dr. Chan in the action was filed with the court, which removed him as a defendant in the action. On July 11, 2008, the court granted a motion to dismiss the Company as a defendant in the action. Blackstone remains a defendant. The Company believes that Blackstone has meritorious defenses to the claims alleged and it intends to defend vigorously against this lawsuit. On September 17, 2007, the Company submitted a claim for indemnification from the escrow fund established in connection with the Merger Agreement for any losses to the Company or Blackstone resulting from this matter. The Company was subsequently notified by legal counsel for the former shareholders that the representative of the former shareholders of Blackstone has objected to the indemnification claim and intends to contest it in accordance with the terms of the Merger Agreement.

Table of Contents

Between January 2007 and May 2007, Blackstone and Orthofix Inc. were named defendants, along with other medical device manufacturers, in three civil lawsuits alleging that Dr. Chan had performed unnecessary surgeries in three different instances. In January 2008, the Company learned that Orthofix Inc. was named a defendant, along with other medical device manufacturers, in a fourth civil lawsuit alleging that Dr. Chan had performed unnecessary surgeries. All four civil lawsuits have been served and were filed in the Circuit Court of White County, Arkansas. The Company has reached a settlement in one of these four civil lawsuits, and the court has entered an order of dismissal. The settlement agreement is not expected to have a material impact on the Company’s consolidated financial position, results of operations or cash flows. The Company believes that the Company and its subsidiaries have meritorious defenses to the claims alleged in the remaining three lawsuits and the Company and its subsidiaries intend to defend vigorously against these lawsuits if they are not settled. On September 17, 2007, the Company submitted a claim for indemnification from the escrow fund established in connection with the Merger Agreement for any losses to the Company or Blackstone resulting from one of these four civil lawsuits. The Company was subsequently notified by legal counsel for the former shareholders that the representative of the former shareholders of Blackstone has objected to the indemnification claim and intends to contest it in accordance with the terms of the Merger Agreement.

Of the total Blackstone purchase price, approximately $50.0 million was placed into an escrow account. As described in the Agreement and Plan of Merger, the Company can make claims for reimbursement from the escrow account for certain defined items relating to the acquisition for which the Company is indemnified. As described in Note 18, the Company has certain contingencies arising from the acquisition that management expects will be reimbursable from the escrow account should the Company have to make a payment to a third party. The Company records the claims against the escrow in an escrow receivable account which is included in other current assets on the consolidated balance sheets. Because the Company believes that the settlement process of escrow claims is complex and all claims may not be reimbursed, management has recorded a partial reserve against the escrow receivable.

The Company is unable to predict the outcome of each of the escrow claims described above in the preceding paragraphs or to estimate the amount, if any, that may ultimately be returned to the Company from the escrow fund and there can be no assurance that the contingencies will not exceed the amount of the escrow account.

In addition to the foregoing claims, the Company has submitted claims for indemnification from the escrow fund established in connection with the Merger Agreement for losses that have or may result from certain claims against Blackstone alleging that plaintiffs and/or claimants were entitled to payments for Blackstone stock options not reflected in Blackstone's corporate ledger at the time of Blackstone's acquisition by the Company, or that their shares or stock options were improperly diluted by Blackstone. To date, the representative of the former shareholders of Blackstone has not objected to approximately $1.5 million in such claims from the escrow fund, with certain claims remaining pending.

The Company cannot predict the outcome of any of the proceedings or claims made against the Company or its subsidiaries described above in the preceding paragraphs and there can be no assurance that the ultimate resolution of any claim will not have a material adverse impact on its consolidated financial position, results of operations, or cash flows.

Table of Contents

In addition to the foregoing, in the normal course of our business, the Company is involved in various lawsuits from time to time and may be subject to certain other contingencies.

United Kingdom Payroll Taxes

In 2007, Intavent Orthofix Limited, the Company’s UK distribution subsidiary, received an inquiry from H.M. Revenue and Customs (HMRC) relating to the tax treatment of gains made by UK employees on the exercise of stock options. The Company is in the process of formulating a response to HMRC. Based on preliminary calculations, a provision of $0.5 million has been provided, of which the Company has paid $0.2 million. The Company cannot predict the ultimate outcome of its discussions with HMRC.

Concentrations of credit risk

There have been no material changes from the information provided in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2007.

Table of Contents

Item 2.

Management’sDiscussionand Analysis of Financial Condition and Results of Operations

The following discussion and analysis addresses our liquidity, financial condition, and the results of our operations for the three and nine months ended September 30, 2008 compared to our results of operations for the three and nine months ended September 30, 2007. These discussions should be read in conjunction with our historical consolidated financial statements and related notes thereto and the other financial information included in this Form 10-Q and in our Annual Report on Form 10-K for the fiscal year ended December 31, 2007.

General

We are a diversified orthopedic products company offering a broad line of surgical and non-surgical products for the Spine, Orthopedics, Sports Medicine and Vascular market sectors. Our products are designed to address the lifelong bone-and-joint health needs of patients of all ages, helping them achieve a more active and mobile lifestyle. We design, develop, manufacture, market and distribute medical equipment used principally by musculoskeletal medical specialists for orthopedic applications. Our main products are invasive and minimally invasive spinal implant products and related human cellular and tissue based products (“HCT/P products”), non-invasive bone growth stimulation products used to enhance the success rate of spinal fusions and to treat non-union fractures, external and internal fixation devices used in fracture treatment, limb lengthening and bone reconstruction; and bracing products used for ligament injury prevention, pain management and protection of surgical repair to promote faster healing. Our products also include a device for enhancing venous circulation, cold therapy, bone cement and devices for removal of bone cement used to fix artificial implants and airway management products used in anesthesia applications.

We have administrative and training facilities in the United States and Italy and manufacturing facilities in the United States, the United Kingdom, Italy and Mexico. We directly distribute our products in the United States, the United Kingdom, Italy, Germany, Switzerland, Austria, France, Belgium, Mexico, Brazil, and Puerto Rico. In several of these and other markets, we also distribute our products through independent distributors.

Our condensed consolidated financial statements include the financial results of the Company and its wholly-owned and majority-owned subsidiaries and entities over which we have control. All intercompany accounts and transactions are eliminated in consolidation.

Our reporting currency is the United States Dollar. All balance sheet accounts, except shareholders’ equity, are translated at period-end exchange rates, and revenue and expense items are translated at weighted average rates of exchange prevailing during the period. Gains and losses resulting from foreign currency transactions are included in other income (expense). Gains and losses resulting from the translation of foreign currency financial statements are recorded in the accumulated other comprehensive income component of shareholders’ equity.

Our financial condition, results of operations and cash flows are not significantly impacted by seasonality trends. However, sales associated with products for elective procedures appear to be influenced by the somewhat lower level of such procedures performed in the late summer. Certain of the Breg® bracing products experience greater demand in the fall and winter corresponding with high school and college football schedules and winter sports. In addition, we do not believe our operations will be significantly affected by inflation. However, in the ordinary course of business, we are exposed to the impact of changes in interest rates and foreign currency fluctuations. Our objective is to limit the impact of such movements on earnings and cash flows. In order to achieve this objective, we seek to balance non-dollar income and expenditures. During the first nine months of 2008, we have used derivative instruments to hedge certain foreign currency fluctuation exposures as well as interest rate exposure on LIBOR-based borrowings. See Item 3 – “Quantitative and Qualitative Disclosures About Market Risk.”

We manage our operations as four business segments: Domestic, Blackstone, Breg, and International. Domestic consists of operations of our subsidiary Orthofix Inc. Blackstone consists of Blackstone’s domestic and international operations. Breg consists of Breg Inc.’s domestic operations and international distributors. International consists of operations which are located in the rest of the world as well as independent export distribution operations. Group Activities are comprised of the operating expenses and identifiable assets of Orthofix International N.V. and its U.S. holding company subsidiary, Orthofix Holdings, Inc.

Table of Contents

Segment and Market Sector Revenues

The following tables display net sales by business segment and net sales by market sector. We keep our books and records and account for net sales, costs of sales and expenses by business segment. We provide net sales by market sector for information purposes only.

Business Segment:

	Three Months Ended September 30,
(In US$ thousands)	2008					2007
	Net Sales		Percent of Total Net Sales			Net Sales		Percent of Total Net Sales			Growth
Domestic	$	47,065		36	%	$	41,971		35	%		12	%

Blackstone		25,338		20	%		29,448		24	%		(14	)%

Breg		22,377		17	%		21,206		17	%		6	%

International		34,521		27	%		28,495		24	%		21	%

Total	$	129,301		100	%	$	121,120		100	%		7	%

	Nine Months Ended September 30,
(In US$ thousands)	2008					2007
	Net Sales		Percent of Total Net Sales			Net Sales		Percent of Total Net Sales			Growth
Domestic	$	138,397		36	%	$	122,718		34	%		13	%

Blackstone		81,093		21	%		85,859		24	%		(6	)%

Breg		66,341		17	%		61,522		17	%		8	%

International		101,541		26	%		91,389		25	%		11	%